Xiid Launches Elite Advisory Board, Enlists Rachel Higham to Help Drive Next Phase of Growth
5.11.2025 12:00:00 CET | Business Wire | Press Release
Xiid Corp., which is revolutionizing cyber defense with zero knowledge networking, today announced it has assembled a distinguished advisory board and added Rachel Higham to this circle of trusted advisors. Formerly Marks & Spencer’s chief digital and technology officer, Higham will serve as a special advisor and consultant, leading Xiid’s go-to-market strategy with hyperscalers, colocation companies and telecom services providers.
“Rachel contributes valuable perspective and experience,” said Xiid CEO Steve Visconti. “Now the new Xiid Advisory Board – which already includes global industry leaders with deep roots at such companies as Alcatel, Capgemini, Deloitte, Microsoft and Vodafone – is even stronger.”
Higham learned of Xiid’s unique approach during her time with Marks & Spencer. In addition to her experience with the multinational retailer, she served as WPP’s CIO, BT’s managing director of IT and MD Asia and Vodafone’s head of cloud and infrastructure centre of excellence.
“Xiid fortifies companies against threats such as ransomware in a way that no other solution can,” said Higham. “Having experienced Xiid’s unrivaled approach firsthand, I am thrilled by the opportunity to share it with other organizations. During recovery from a destructive cyberattack, it is often difficult to maintain a secure perimeter as you restore critical systems and integrations. Xiid's secure tunnelling technology makes that incredibly simple, increasing speed to recovery and reducing both risk and costs.”
The Xiid Advisory Board brings together an impressive group of top global executives with board-level experience across the telecom, finance, and defense sectors. These power players have led multi-billion-dollar technology, security, and transformation initiatives.
“Xiid is redefining how secure connectivity is designed – not as an add-on, but as a foundation of modern enterprise architecture,” said Xiid Advisory Board Member Albert Hitchcock. “I’m excited to contribute to Xiid’s mission to make organizations stronger and more resilient.”
Hitchcock is a global technology leader recognized for large-scale IT transformation and cloud innovation, having served as a CIO at Vodafone. Xiid Advisory Board member Bertrand Alexis contributes more than 25 years’ experience supporting growing international companies. Jérôme Desbonnet is a C-level cybersecurity and cloud leader at Capgemini. Kathryn Dougherty is an advisor on cyber frameworks and regulatory alignment. Formerly CEO at Alcatel-Lucent RT and vice president-cybersecurity at Capgemini, Serge Dujardin adds advisory board member to his title at Xiid, where he serves as general manager and executive vice president-international. Michel Emelianoff, formerly CEO of Alcatel-Lucent Enterprise, is a specialist in enterprise networking, cloud, and IoT systems.
Andy MacLeod, who has held C-level roles at Verizon and Vodafone, brings expertise in global telecom and infrastructure. Kathryn Mihalich is a specialist in compliance strategy, data governance, and security architecture. Ericsson leader Ola Persson is a telecom and 5G infrastructure expert focusing on large-scale network design and operations. Anna Vikström Persson is a leadership and culture transformation specialist for multinational organizations, having served in that function for such companies as Ericsson and Sandvik. A former senior partner and vice chair for Deloitte UK, William Touche is a specialist in board governance, financial systems, and leadership transformation. A former Houghton Mifflin Harcourt CEO who has served as a vice president at Microsoft, Oracle and PeopleSoft, Linda Zecher is a renowned executive with deep expertise in digital transformation, the public sector, and enterprise growth.
“Our advisory board brings together technology leaders who have shaped the world’s largest enterprises,” said Visconti. “Their commitment adds to Xiid’s strength as we navigate strategic expansion, ensure product-market fit and accelerate enterprise adoption on our zero knowledge networking mission to help organizations achieve true prevention by design.”
About Xiid
Xiid is revolutionizing cybersecurity with its zero knowledge networking (ZKN) architecture, which powers Xiid Identity and Access Management and Xiid SealedTunnel. Xiid’s ZKN architecture goes beyond zero trust, empowering organizations to shift from reacting to attacks to eliminating the attack surface altogether. For more information about Xiid and how its unprecedented security can make you stronger, visit www.xiid.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251105683579/en/
Contacts
Media Contact
Emily Roberts
PRforXiid@bospar.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom